Premium
Durable responses after CD19‐targeted CAR‐T cell immunotherapy with concurrent ibrutinib for CLL after prior ibrutinib failure
Author(s) -
Gauthier J.,
Hirayama A.V.,
Hay K.A.,
Lymp J.,
Li D.,
Sheih A.,
Purushe J.,
Pender B.S.,
Hawkins R.M.,
Vakil A.,
Phi T.,
Steinmetz R.N.,
Riddell S.R.,
Maloney D.G.,
Turtle C.J.
Publication year - 2019
Publication title -
hematological oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.918
H-Index - 44
eISSN - 1099-1069
pISSN - 0278-0232
DOI - 10.1002/hon.126_2629
Subject(s) - ibrutinib , medicine , chronic lymphocytic leukemia , cytokine release syndrome , oncology , chimeric antigen receptor , leukemia , immunology , immunotherapy , cancer